On November 3, 2023 (the ?Effective Date?), Nanomix Corporation appointed David Ludvigson as interim chief executive officer of the Company, effective immediately. Mr. Ludvigson succeeds Dr. Thomas Schlumpberger who unexpectedly passed away on November 2, 2023. Mr. Ludvigson served as chief executive officer of the Company from June 2021 to July 2022, chief financial officer from June 2021 until January 2023 and as a director since June 2021.

From June 2013 to June 2021, he served as CEO of Nanomix Inc. From October 2009 through present day, Mr. Ludvigson has served as President of Knight Ludvigson Advisors providing advisory and business consulting services to Life Science and Technology companies including M&A, financing, business strategy, go to market planning and sales channel strategy and implementation. Mr. Ludvigson serves on the board of directors of Imagion Biosystems Inc., One BioMed PTE LTD (privately held), Incando Therapeutics Inc. (privately held) and China Stem Cells Ltd. (privately held). Mr. Ludvigson received his BS and MAS in Accounting from Gies College of Business ?

University of Illinois Urbana-Champaign.